Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
31.8M
-
Shares change
-
+1.2M
-
Total reported value, excl. options
-
$404M
-
Value change
-
-$100M
-
Put/Call ratio
-
0.72
-
Number of buys
-
76
-
Number of sells
-
-68
-
Price
-
$12.71
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2019
186 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2019.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.8M shares
of 49.6M outstanding shares and own 64% of the company stock.
Largest 10 shareholders include STATE STREET CORP (4.76M shares), VANGUARD GROUP INC (3.07M shares), Partner Fund Management, L.P. (2.84M shares), Sarissa Capital Management LP (1.42M shares), Palo Alto Investors LP (1.41M shares), FRED ALGER MANAGEMENT INC (1.19M shares), CITADEL ADVISORS LLC (1.13M shares), MACQUARIE GROUP LTD (1.05M shares), DEUTSCHE BANK AG\ (977K shares), and NORGES BANK (655K shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.